Hologic (NASDAQ:HOLX) was upgraded by investment analysts at Cowen from a “market perform” rating to an “outperform” rating in a research report issued to clients and investors on Monday.

A number of other research firms also recently commented on HOLX. Needham & Company LLC reiterated a “buy” rating and issued a $48.00 price objective (up previously from $46.00) on shares of Hologic in a report on Tuesday, December 5th. Goldman Sachs Group upgraded Hologic from a “buy” rating to a “conviction-buy” rating and increased their price target for the stock from $45.00 to $50.00 in a report on Friday. Piper Jaffray Companies restated a “buy” rating and issued a $48.00 price target on shares of Hologic in a report on Thursday, November 9th. Stifel Nicolaus restated a “buy” rating and issued a $45.00 price target (down from $48.00) on shares of Hologic in a report on Monday, October 9th. Finally, Royal Bank Of Canada restated a “hold” rating and issued a $42.00 price target on shares of Hologic in a report on Friday, September 22nd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Hologic presently has an average rating of “Buy” and a consensus price target of $47.62.

Shares of Hologic (NASDAQ:HOLX) opened at $42.69 on Monday. The company has a market capitalization of $11,768.93, a PE ratio of 21.13, a P/E/G ratio of 2.06 and a beta of 0.95. The company has a quick ratio of 0.61, a current ratio of 0.79 and a debt-to-equity ratio of 0.79. Hologic has a fifty-two week low of $35.76 and a fifty-two week high of $46.80.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.01. The business had revenue of $802.90 million during the quarter, compared to the consensus estimate of $792.54 million. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The firm’s revenue was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.52 earnings per share. equities analysts expect that Hologic will post 2.12 EPS for the current fiscal year.

In other news, Director Lawrence M. Levy sold 7,138 shares of the company’s stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $37.38, for a total transaction of $266,818.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Karleen Marie Oberton sold 1,256 shares of the company’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $39.29, for a total value of $49,348.24. Following the transaction, the vice president now directly owns 9,406 shares of the company’s stock, valued at $369,561.74. The disclosure for this sale can be found here. Insiders have sold 28,833 shares of company stock valued at $1,107,270 over the last ninety days. 0.79% of the stock is owned by insiders.

Hedge funds have recently bought and sold shares of the company. Grove Bank & Trust boosted its position in shares of Hologic by 115.8% during the third quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock worth $105,000 after buying an additional 1,535 shares during the period. Hall Laurie J Trustee boosted its position in shares of Hologic by 10.2% during the second quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock worth $110,000 after buying an additional 225 shares during the period. Commonwealth Bank of Australia boosted its position in shares of Hologic by 31.0% during the second quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock worth $114,000 after buying an additional 600 shares during the period. MPS Loria Financial Planners LLC acquired a new position in shares of Hologic during the second quarter worth about $191,000. Finally, National Asset Management Inc. acquired a new position in shares of Hologic during the second quarter worth about $203,000. 98.08% of the stock is owned by institutional investors.

WARNING: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/12/11/cowen-upgrades-hologic-holx-to-outperform.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.